Halozyme Therapeutics, Inc. Aktie News

This medical technology stock is back in a buy zone and nearing its all-time high.

Halozyme Therapeutics is positioned for multi-year growth, leveraging recent acquisitions and robust royalty revenue momentum.

Of the five stocks, three are benefiting from data center expansion.

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of  $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges:  - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2  - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2  - Increa...

Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions.

SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, ...

Explore the exciting world of Halozyme Therapeutics (HALO 0.85%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!